Drug Price Transparency
AHA letter to the US Senate supporting Amendment #3787 to address 鈥榦ut-of-control cost鈥 of prescription drugs.
AHA comments on the 340B section of the Department of Health and Human Services鈥 Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
AHA commends MedPAC and HHS for voicing significant concerns about rising pharmaceutical costs.
The 黑料正能量 Association and others support Senators Grassley and Feinstein of the Senate Judiciary Committee for their leadership and commitment to reducing out-of-control prescription drug prices and stopping anti-competitive abuses that keep drug prices high.
Read the full letter below鈥
AHA comments to HRSA regarding proposed rule that would further delay the effective date for implementing final regulations regarding the 340B Drug Pricing Program ceiling price and drug manufacturers鈥 civil monetary penalties (CMPs) for violations of the ceiling price.
Medicare D prescription drug plan should not prevent pharmacies from telling customers when they could pay less for a drug by paying cash, the Centers for Medicare & Medicaid Services told plan sponsors yesterday.
The Food and Drug Administration today announced new efforts to spotlight situations where drugmakers may be pursuing 鈥済aming tactics鈥 to delay generic competition.
The Centers for Medicare & Medicaid Services today updated the Parts B and D drug spending dashboards with 2016 information.
The AHA Friday submitted comments to Sens. Bill Cassidy (R-LA), Michael Bennet (D-CO), Chuck Grassley (R-IA), Tom Carper (D-DE), Todd Young (R-IN) and Claire McCaskill (D-MO) as they develop legislation to improve price transparency in the health care market and lower costs.
The Campaign for Sustainable Rx Pricing released a digital and television ad urging Congress to pass the Creating and Restoring Equal Access to Equivalent Samples Act to lower drug prices.